Key clinical point:
Major finding: Idarubicin was associated with a higher risk of grade 3 or 4 hepatotoxicity, and vincristine was associated with a borderline risk.
Study details: Retrospective review of 51 PEG-ASP dosing events in 26 adult patients with ALL.
Disclosures: The study was internally funded. The authors reported having no relevant conflicts of interest.
Source: Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.
Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.
This Week's Must Reads
Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052
CAVEAT shows venetoclax plus chemo appropriate for older, fit AML patients , Wei AH et al. EHA Congress, Abstract S1564.
Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.
Patients who develop AML may have detectable mutations years earlier, Desai P et al. Nat Med. 2018;24:1015-23.
Oral administration of arsenic + ATRA effective for APML, Zhu HH et al. Lancet Oncol. 2018;19:871-9.
Must Reads in ALL (Acute Lymphoblastic Leukemia)
ALL patients' liver toxicities linked to antibiotics, other therapies, Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.
Patient-specific risk factors for BCC, SCC examined in study, Scott J et al. Presentation at American College of Mohs Surgery, May 2018.
Getting to MRD in ALL boosted survival, Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.
Pediatric cancers rising, Siegel DA et al. ASPHO 2018, Abstract 605.
In T-ALL, methotrexate and nelarabine boosted chemo response, Dunsmore KP et al. ASCO 2018, Abstract 10500.